Compare LEO & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LEO | SENS |
|---|---|---|
| Founded | 1987 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Industrial Machinery/Components |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 346.3M | 397.1M |
| IPO Year | N/A | 2014 |
| Metric | LEO | SENS |
|---|---|---|
| Price | $5.95 | $8.94 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $13.67 |
| AVG Volume (30 Days) | 290.4K | ★ 587.0K |
| Earning Date | 01-01-0001 | 11-09-2026 |
| Dividend Yield | ★ 4.01% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | N/A | ★ $16,389,000.00 |
| Revenue This Year | N/A | $82.21 |
| Revenue Next Year | N/A | $55.63 |
| P/E Ratio | $148.75 | ★ N/A |
| Revenue Growth | N/A | ★ 19.85 |
| 52 Week Low | $5.41 | $4.79 |
| 52 Week High | $6.55 | $10.64 |
| Indicator | LEO | SENS |
|---|---|---|
| Relative Strength Index (RSI) | 62.12 | 52.60 |
| Support Level | $5.42 | $8.45 |
| Resistance Level | $6.50 | $10.26 |
| Average True Range (ATR) | 0.08 | 0.60 |
| MACD | 0.05 | 0.15 |
| Stochastic Oscillator | 96.15 | 71.20 |
BNY Mellon Strategic Municipals, Inc. is a diversified closed-end management investment company. The fund's investment objective is to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital. Its products include equity and fixed income mutual funds, retail money market funds, government/treasury money market funds, institutional money market funds, and others. The company and its affiliates, as well as others involved in the management, sales, investment activities, business operations, or distribution of the fund, are engaged in businesses and have interests other than those of managing the fund.
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.